Trial · NCT00478192
Results by group112
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 112
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation. | Regimen 1 Conivaptan QD | Baseline (N= 20; 20; 9) | 126.03 | Standard Deviation 4.017 | mEq/L |
| Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation. | Regimen 2 Conivaptan BID | Baseline (N= 20; 20; 9) | 126.39 | Standard Deviation 3.581 | mEq/L |
| Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation. | Regimen 3 Placebo | Baseline (N= 20; 20; 9) | 125.55 | Standard Deviation 3.648 | mEq/L |
| Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation. | Regimen 1 Conivaptan QD | Hour 48 (N=19; 17; 8) | 130.4 | Standard Deviation 5.21 | mEq/L |
| Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation. | Regimen 2 Conivaptan BID | Hour 48 (N=19; 17; 8) | 133.4 | Standard Deviation 4.82 | mEq/L |
| Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation. | Regimen 3 Placebo | Hour 48 (N=19; 17; 8) | 127.6 | Standard Deviation 2.36 | mEq/L |
| Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation. | Regimen 1 Conivaptan QD | Change from Baseline (N=19; 17; 8) | 4.00 | Standard Deviation 3.80 | mEq/L |
| Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation. | Regimen 2 Conivaptan BID | Change from Baseline (N=19; 17; 8) | 7.36 | Standard Deviation 4.04 | mEq/L |
| Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation. | Regimen 3 Placebo | Change from Baseline (N=19; 17; 8) | 1.16 | Standard Deviation 2.86 | mEq/L |
| Change From Baseline in Serum Sodium Level at Each Time Point Through the 48 Hour Assessment | Regimen 1 Conivaptan QD | Baseline (N=20; 20; 9) | 126.03 | Standard Deviation 4.02 | mEq/L |
| Change From Baseline in Serum Sodium Level at Each Time Point Through the 48 Hour Assessment | Regimen 2 Conivaptan BID | Baseline (N=20; 20; 9) | 126.39 | Standard Deviation 3.58 | mEq/L |
| Change From Baseline in Serum Sodium Level at Each Time Point Through the 48 Hour Assessment | Regimen 3 Placebo | Baseline (N=20; 20; 9) | 125.55 | Standard Deviation 3.65 | mEq/L |
| Change From Baseline in Serum Sodium Level at Each Time Point Through the 48 Hour Assessment | Regimen 1 Conivaptan QD | Hour 4 (N=19; 20; 8) | 128.03 | Standard Deviation 4.62 | mEq/L |
| Change From Baseline in Serum Sodium Level at Each Time Point Through the 48 Hour Assessment | Regimen 2 Conivaptan BID | Hour 4 (N=19; 20; 8) | 128.47 | Standard Deviation 4.21 | mEq/L |
| Change From Baseline in Serum Sodium Level at Each Time Point Through the 48 Hour Assessment | Regimen 3 Placebo | Hour 4 (N=19; 20; 8) | 125.80 | Standard Deviation 4.63 | mEq/L |
| Change From Baseline in Serum Sodium Level at Each Time Point Through the 48 Hour Assessment | Regimen 1 Conivaptan QD | Change at Hour 4 (N=19; 20; 8) | 1.59 | Standard Deviation 2.32 | mEq/L |
| Change From Baseline in Serum Sodium Level at Each Time Point Through the 48 Hour Assessment | Regimen 2 Conivaptan BID | Change at Hour 4 (N=19; 20; 8) | 2.08 | Standard Deviation 2.65 | mEq/L |
| Change From Baseline in Serum Sodium Level at Each Time Point Through the 48 Hour Assessment | Regimen 3 Placebo | Change at Hour 4 (N=19; 20; 8) | -0.63 | Standard Deviation 2.77 | mEq/L |
| Change From Baseline in Serum Sodium Level at Each Time Point Through the 48 Hour Assessment | Regimen 1 Conivaptan QD | Hour 12 (N=19; 19; 7) | 128.22 | Standard Deviation 5.27 | mEq/L |
| Change From Baseline in Serum Sodium Level at Each Time Point Through the 48 Hour Assessment | Regimen 2 Conivaptan BID | Hour 12 (N=19; 19; 7) | 130.85 | Standard Deviation 5.88 | mEq/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00478192/results